Paraoxonase 1 R/Q alleles are associated with differential accumulation of saturated versus 20:5n3 fatty acid in human adipose tissue

Journal of Lipid Research

Volumn 51, Issue 7, 2010, Pages 1991-2000

  Zafiropoulos, Alexandros ^a   Linardakis, Manolis ^a   Jansen, Eugene H J M ^b   Tsatsakis, Aristidis M ^a   Kafatos, Antonis ^a   Tzanakakis, George N ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Dyslipidemia; Lipid homeostasis; Lipidomics

Indexed keywords

APOLIPOPROTEIN B; ARACHIDONIC ACID; ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; DIHOMO GAMMA LINOLENIC ACID; DOCOSAHEXAENOIC ACID; HOMOCYSTEINE; ICOSAPENTAENOIC ACID; LINOLEIC ACID; LINOLENIC ACID; MONOUNSATURATED FATTY ACID; POLYUNSATURATED FATTY ACID; SATURATED FATTY ACID; TRANS FATTY ACID; ARYLDIALKYLPHOSPHATASE; FATTY ACID; LIPID; LIPOPROTEIN; UNSATURATED FATTY ACID;

ADIPOSE TISSUE; ADULT; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GLUCOSE BLOOD LEVEL; GREECE; HUMAN; IRON BLOOD LEVEL; LIPID COMPOSITION; LIPIDOMICS; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; AGED; ALLELE; ANIMAL; BLOOD; CROSS-SECTIONAL STUDY; GENETICS; GENOTYPE; METABOLISM; MIDDLE AGED; QUESTIONNAIRE;

ADIPOSE TISSUE; ADULT; AGED; ALLELES; ANIMALS; ARYLDIALKYLPHOSPHATASE; CROSS-SECTIONAL STUDIES; EICOSAPENTAENOIC ACID; FATTY ACIDS; FATTY ACIDS, UNSATURATED; FEMALE; GENOTYPE; GREECE; HUMANS; LIPIDS; LIPOPROTEINS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; QUESTIONNAIRES;

EID: 77953481405     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.P004960     Document Type: Article

References (47)

1. Hassett, C., R. J. Richter, R. Humbert, C. Chapline, J. W. Crabb, C. J. Omiecinski, and C. E. Furlong. 1991. Characterization of cDNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence. Biochemistry. 30: 10141-10149.
2. Mackness, M. I., S. Arrol, and P. N. Durrington. 1991. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 286: 152-154.
3. Mertens, A., and P. Holvoet. 2001. Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB J. 15: 2073-2084.
4. Aviram, M., M. Rosenblat, C. L. Bisgaier, R. S. Newton, S. L. Primo-Parmo, and B. N. La Du. 1998. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J. Clin. Invest. 101: 1581-1590. (Pubitemid 28198486)
5. Shih, D. M., L. Gu, Y. R. Xia, M. Navab, W. F. Li, S. Hama, L. W. Castellani, C. E. Furlong, L. G. Costa, A. M. Fogelman, et al. 1998. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 394: 284-287.
6. She, Z. G., W. Zheng, Y. S. Wei, H. Z. Chen, A. B. Wang, H. L. Li, G. Liu, R. Zhang, J. J. Liu, W. B. Stallcup, et al. 2009. Human paraoxonase gene cluster transgenic overexpression represses atherogenesis and promotes atherosclerotic plaque stability in ApoE-null mice. Circ. Res. 104: 1160-1168.
7. Adkins, S., K. N. Gan, M. Mody, and B. N. La Du. 1993. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am. J. Hum. Genet. 52: 598-608. (Pubitemid 23311330)
8. Humbert, R., D. A. Adler, C. M. Disteche, C. Hassett, C. J. Omiecinski, and C. E. Furlong. 1993. The molecular basis of the human serum paraoxonase activity polymorphism. Nat. Genet. 3: 73-76.
9. Davies, H. G., R. J. Richter, M. Keifer, C. A. Broomfield, J. Sowalla, and C. E. Furlong. 1996. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat. Genet. 14: 334-336.
10. Garin, M. C., R. W. James, P. Dussoix, H. Blanche, P. Passa, P. Froguel, and J. Ruiz. 1997. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J. Clin. Invest. 99: 62-66.
11. Rosenblat, M., R. Coleman, S. T. Reddy, and M. Aviram. 2009. Paraoxonase 2 attenuates macrophage triglyceride accumulation via inhibition of diacylglycerol acyltransferase 1. J. Lipid Res. 50: 870-879.
12. Marsillach, J., B. Mackness, M. Mackness, F. Riu, R. Beltran, J. Joven, and J. Camps. 2008. Immunohistochemical analysis of paraoxonases-1, 2, and 3 expression in normal mouse tissues. Free Radic. Biol. Med. 45: 146-157.
13. Tirosh, A., R. Potashnik, N. Bashan, and A. Rudich. 1999. Oxidative stress disrupts insulin-induced cellular redistribution of insulin receptor substrate-1 and phosphatidylinositol 3-kinase in 3T3-L1 adipocytes. A putative cellular mechanism for impaired protein kinase B activation and GLUT4 translocation. J. Biol. Chem. 274: 10595-10602.
14. Vardavas, C. I., M. K. Linardakis, C. M. Hatzis, N. Malliaraki, W. H. Saris, and A. G. Kafatos. 2008. Smoking status in relation to serum folate and dietary vitamin intake. Tob Induc Dis. 4: 8.
15. Mamalakis, G., M. Kiriakakis, G. Tsibinos, E. Jansen, H. Cremers, C. Strien, C. Hatzis, J. Moschandreas, M. Linardakis, D. Kromhout, et al. 2008. Lack of an association of depression with n-3 polyunsaturated fatty acids in adipose tissue and serum phospholipids in healthy adults. Pharmacol. Biochem. Behav. 89: 6-10.
16. Vardavas, C. I., M. Linardakis, C. Hatzis, W. Sarris, and A. Kafatos. 2008. Prevalence of obesity and physical inactivity among farmers from Crete (Greece), four decades after the Seven Countries Study. Nutr. Metab. Cardiovasc. Dis. 19: 153-155.
17. Tsatsakis, A. M., A. Zafiropoulos, M. Tzatzarakis, G. N. Tzanakakis, and A. Kafatos. 2008. Relation ofPON1andCYP1A1genetic polymorphisms to clinical findings in a cross-sectional study of a Greek rural population professionally exposed to pesticides. Toxicol. Lett. 10.1016/j.toxlet.2008.10.018.
18. Zafiropoulos, A., N. Crikas, A. M. Passam, and D. A. Spandidos. 2004. Significant involvement of CCR2-64I and CXCL12-3a in the development of sporadic breast cancer. J. Med. Genet. 41: e59.
19. Beynen, A. C., and M. B. Katan. 1985. Rapid sampling and longterm storage of subcutaneous adipose-tissue biopsies for determination of fatty acid composition. Am. J. Clin. Nutr. 42: 317-322.
20. Mamalakis, G., M. Kiriakakis, G. Tsibinos, and A. Kafatos. 2004. Depression and adipose polyunsaturated fatty acids in the survivors of the Seven Countries Study population of Crete. Prostaglandins Leukot. Essent. Fatty Acids. 70: 495-501.
21. Vasan, R. S., M. G. Larson, E. P. Leip, J. C. Evans, C. J. O'Donnell, W. B. Kannel, and D. Levy. 2001. Impact of high-normal blood pressure on the risk of cardiovascular disease. N. Engl. J. Med. 345: 1291-1297.
22. Chobanian, A. V., G. L. Bakris, H. R. Black, W. C. Cushman, L. A. Green, J. L. Izzo, Jr., D. W. Jones, B. J. Materson, S. Oparil, J. T. Wright, Jr., et al. 2003. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 289: 2560-2572.
23. van Himbergen, T. M., M. Roest, J. de Graaf, E. H. Jansen, H. Hattori, J. J. Kastelein, H. A. Voorbij, A. F. Stalenhoef, and L. J. van Tits. 2005. Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia. J. Lipid Res. 46: 445-451.
24. Richter, R. J., and C. E. Furlong. 1999. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics. 9: 745-753.
25. Rosenblat, M., and M. Aviram. 2009. Paraoxonases role in the prevention of cardiovascular diseases. Biofactors. 35: 98-104.
26. Hedrick, C. C., K. Hassan, G. P. Hough, J. H. Yoo, S. Simzar, C. R. Quinto, S. M. Kim, A. Dooley, S. Langi, S. Y. Hama, et al. 2000. Short-term feeding of atherogenic diet to mice results in reduction of HDL and paraoxonase that may be mediated by an immune mechanism. Arterioscler. Thromb. Vasc. Biol. 20: 1946-1952.
27. Leviev, I., and R. W. James. 2000. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler. Thromb. Vasc. Biol. 20: 516-521. (Pubitemid 30086111)
28. Van Lenten, B. J., A. C. Wagner, D. P. Nayak, S. Hama, M. Navab, and A. M. Fogelman. 2001. High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection. Circulation. 103: 2283-2288.
29. Li, H. L., D. P. Liu, and C. C. Liang. 2003. Paraoxonase gene polymorphisms, oxidative stress, and diseases. J. Mol. Med. 81: 766-779.
30. Watzinger, N., H. Schmidt, M. Schumacher, R. Schmidt, B. Eber, F. M. Fruhwald, R. Zweiker, G. M. Kostner, and W. Klein. 2002. Human paraoxonase 1 gene polymorphisms and the risk of coronary heart disease: a community-based study. Cardiology. 98: 116-122.
31. Mackness, B., G. K. Davies, W. Turkie, E. Lee, D. H. Roberts, E. Hill, C. Roberts, P. N. Durrington, and M. I. Mackness. 2001. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler. Thromb. Vasc. Biol. 21: 1451-1457.
32. Bonafe, M., F. Marchegiani, M. Cardelli, F. Olivieri, L. Cavallone, S. Giovagnetti, C. Pieri, M. Marra, R. Antonicelli, L. Troiano, et al. 2002. Genetic analysis of paraoxonase (PON1) locus reveals an increased frequency of Arg192 allele in centenarians. Eur. J. Hum. Genet. 10: 292-296.
33. Hegele, R. A. 1999. Paraoxonase genes and disease. Ann. Med. 31: 217-224.
34. Mackness, B., M. I. Mackness, S. Arrol, W. Turkie, K. Julier, B. Abuasha, J. E. Miller, A. J. Boulton, and P. N. Durrington. 1998. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis. 139: 341-349.
35. Ikeda, Y., T. Suehiro, M. Inoue, Y. Nakauchi, T. Morita, K. Arii, H. Ito, Y. Kumon, and K. Hashimoto. 1998. Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin-dependent diabetes mellitus. Metabolism. 47: 598-602.
36. Abbott, C. A., M. I. Mackness, S. Kumar, A. J. Boulton, and P. N. Durrington. 1995. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler. Thromb. Vasc. Biol. 15: 1812-1818.
37. Leus, F. R., M. Zwart, J. J. Kastelein, and H. A. Voorbij. 2001. PON2 gene variants are associated with clinical manifestations of cardiovascular disease in familial hypercholesterolemia patients. Atherosclerosis. 154: 641-649.
38. Malin, R., R. Laaksonen, J. Knuuti, T. Janatuinen, R. Vesalainen, P. Nuutila, and T. Lehtimaki. 2001. Paraoxonase genotype modifies the effect of pravastatin on high-density lipoprotein cholesterol. Pharmacogenetics. 11: 625-633.
39. Fanella, S., S. B. Harris, T. K. Young, A. J. Hanley, B. Zinman, P. W. Connelly, and R. A. Hegele. 2000. Association between PON1 L/M55 polymorphism and plasma lipoproteins in two Canadian aboriginal populations. Clin. Chem. Lab. Med. 38: 413-420.
40. Raclot, T. 2003. Selective mobilization of fatty acids from adipose tissue triacylglycerols. Prog. Lipid Res. 42: 257-288.
41. Steinberg, D. 1963. Fatty acid mobilization-mechanisms of regulation and metabolic consequences. Biochem. Soc. Symp. 24: 111-143.
42. Hollenberg, C. H., and D. E. Douglas. 1962. Effect of adrenaline, corticotropin, fasting, and diabetes on the composition of the longchain fatty acids of rat epididymal fat. Nature. 193: 1074-1075.
43. Body, D. R. 1988. The lipid composition of adipose tissue. Prog. Lipid Res. 27: 39-60.
44. Raclot, T., and R. Groscolas. 1994. Individual fish-oil n-3 polyunsaturated fatty acid deposition and mobilization rates for adipose tissue of rats in a nutritional steady state. Am. J. Clin. Nutr. 60: 72-78. (Pubitemid 24215757)
45. Raclot, T., D. Langin, M. Lafontan, and R. Groscolas. 1997. Selective release of human adipocyte fatty acids according to molecular structure. Biochem. J. 324: 911-915. (Pubitemid 27285551)
46. Raclot, T., and R. Groscolas. 1995. Selective mobilization of adipose tissue fatty acids during energy depletion in the rat. J. Lipid Res. 36: 2164-2173.
47. Ahmed, Z., A. Ravandi, G. F. Maguire, A. Emili, D. Draganov, B. N. La Du, A. Kuksis, and P. W. Connelly. 2001. Apolipoprotein A-I promotes the formation of phosphatidylcholine core aldehydes that are hydrolyzed by paraoxonase (PON-1) during high density lipoprotein oxidation with a peroxynitrite donor. J. Biol. Chem. 276: 24473-24481.